Action TRVX CIRCIO HOLDING ASA
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Circio Holding ASA

Actions

TRVX

NO0013033795

Marché Fermé - Oslo Bors
Autres places de cotation
 16:45:00 30/04/2024 		Varia. 5j. Varia. 1 janv.
2,5 NOK +4,17 % Graphique intraday de Circio Holding ASA -4,58 % -65,28 %
25/04 Circio Holding ASA publie ses résultats pour l'exercice clos le 31 décembre 2023 CI
17/04 Circio annonce la preuve de concept in vivo de sa plateforme d'ARN circulaire circVec et le renforcement de son activité de thérapie génique CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds
Circio : Annual Report 2023 Report
Circio Holding ASA: Annual Report 2023
Circio Holding ASA Reports Earnings Results for the Full Year Ended December 31, 2023
Circio Holding ASA: Requested Conversion of Convertible Bonds
Circio Establishes In Vivo Proof-of-Concept for Circular RNA Platform
Circio to Raise Up to NOK60 Million via Rights Issue
Circio Terminates Cancer Vaccine License Deal in China
Circio : Company update 17 April 2024
Circio announces in vivo proof-of-concept for its circVec circular RNA platform technology and reinforced gene therapy focus
Circio Announces in Vivo Proof-Of-Concept for Its circVec circular RNA Platform Technology and Reinforced Gene Therapy Focus
Circio announces intention to raise around NOK 50-60 million in Q2 2024 to extend cash runway to Q2 2025
Circio terminates TG01 cancer vaccine license option agreement with IOVaxis in China for non-payment
Circio Holding ASA Terminates TG01 Cancer Vaccine License Option Agreement with IOVaxis therapeutics in China for Non-Payment
Circio Holding ASA: Requested Conversion of Convertible Bonds
Circio Partner Exercises Option to License Cancer Vaccine in China
Circio announces that partner IOVaxis Therapeutics has exercised the option for an exclusive license to mutant RAS cancer vaccine TG01 in China
Circio Holding ASA Announces Partner IOVaxis Therapeutics Exercises the Option for an Exclusive License to Mutant RAS Cancer Vaccine TG01 in China
Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds
Circio Holding ASA: Approval and publication of prospectus
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action TRVX
  4. Actualités Circio Holding ASA
  5. Autres langues